ATAI — AtaiBeckley Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2081043 ·
Last close
$7.38
Market Cap
$2.74B
52W High
$7.45
52W Low
$3.67
ADV30
15,960,412
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 954,000 | — | -30,159,000 | -29,782,000 | 264,877,000 | 43,102,000 | 66,098,000 |
| Dec 2025 | 1,066,000 | — | -39,353,000 | -544,813,000 | 292,723,000 | 85,300,000 | 70,722,000 |
| Sep 2025 | 749,000 | — | -28,407,000 | -61,074,000 | 239,820,000 | 30,402,000 | 79,912,000 |
| Jun 2025 | 719,000 | — | -25,245,000 | -27,729,000 | 189,204,000 | 61,940,000 | 45,279,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-105,924,000
Investing CF
$-119,766,000
Financing CF
$210,697,000
CapEx
$-10,868,000
Dividends Paid
—
Buybacks
$-4,468,000
EPS Diluted TTM
$-2.23
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,390,036,000
Inventory
—
Receivables
$14,709,000
ST Investments
$187,665,000
EBIT TTM
$-663,060,000
Pretax Income TTM
$-663,322,000
Interest Exp TTM
$262,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,472,000
EBITDA
$-140,791,008
Free Cash Flow
$-74,669,752
Enterprise Value
$2,515,529,216
Total Cash
$225,808,000
Total Debt
$4,285,000
Shares Out
370,864,669
Trailing EPS
$-2.79
Book Value
$0.48
ROE
-417.2%
ROA
-39.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,089,000 | -113,347,000 | -660,047,000 | 292,723,000 | 70,722,000 | — | -102,675,000 |
| Dec 2024 | 308,000 | -102,166,000 | -149,269,000 | 159,387,000 | 42,833,000 | — | -82,437,000 |
| Dec 2023 | 314,000 | -123,026,000 | -40,224,000 | 293,478,000 | 49,162,000 | — | -84,118,000 |
| Dec 2022 | 233,000 | -144,430,000 | -152,385,000 | 305,441,000 | 39,675,000 | — | -104,467,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.49
Max Pain — expiry 2026-09-18
max pain strike: $7.00 · spot: $7.38 · call oi: 4,591 · put oi: 638
Expected Move to 2026-09-18:
±$0.55
(7.45%) —
implied range
$6.83 –
$7.93
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | $2.73B | $26.27 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.72B | $24.02 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.62B | $45.11 | — |
| PHVS | Pharvaris N.V. | $2.62B | $37.31 | — |
| ZLAB | Zai Lab Ltd | $2.88B | $25.64 | — |
News headlines (Yahoo Finance, 1h cache)
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
2026-08-21 05:16 · Yahoo
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
2026-08-07 13:55 · Yahoo
Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares
2026-08-05 17:43 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-08-02 22:26 · Yahoo
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
2026-07-22 17:25 · Yahoo
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
2026-07-17 15:31 · Yahoo
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics
2026-07-17 12:37 · Yahoo
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued
2026-07-17 10:08 · Yahoo
Eli Lilly's $3.8bn psychedelics bet is built on British science
2026-07-17 09:01 · Yahoo
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
2026-07-17 00:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.